REFERENCIAS BIBLIOGRÁFICAS

Material que avala los efectos probióticos

1. Anukam K, Reid G. 2007. Probiotics: 100 years (1907-2007) after Elie Metchnikoff’s Observation. Communicating Current Research and Educational Topics and Trends in Applied Microbiology 2:466–474.

2. Cutting SM. 2011. Bacillus probiotics. Food Microbiol 28:214–220.

3. Casula G, Cutting SM. 2002. Bacillus Probiotics: Spore Germination in the Gastrointestinal Tract. Applied and Environmental Microbiology 68:2344–2352.

4. Peys E, Varghese J, Suresh P, Vandenkerc J, hemel JV, Chaniyilpa N, Sas B. 2007. Effects of Bacillus subtilis PB6 (ATCC – PTA 6737) on Clostridium difficile Associated Diarrhea (CDAD) and Inflammatory Bowel Disease (IBD) in Animal Models. American Journal of Infectious Diseases 3:255–266.

5. Bernardeau M, Lehtinen MJ, Forssten SD, Nurminen P. 2017. Importance of the gastrointestinal life cycle of Bacillus for probiotic functionality. Journal of Food Science and Technology 54:2570–2584.

6. Mazza P. 1994. The use of Bacillus subtilis as an antidiarrhoeal microorganism. Boll Chim Farm 133:3–18.

7. LeBlanc JG, Chain F, Martín R, Bermúdez-Humarán LG, Courau S, Langella P. 2017. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb Cell Fact 16.

8. Ilinskaya ON, Ulyanova VV, Yarullina DR, Gataullin IG. 2017. Secretome of Intestinal Bacilli: A Natural Guard against Pathologies. Frontiers in Microbiology 8.

9. Rodriguez Ayala F, Bauman C, Bartolini M, Saball E, Salvarrey M, Leñini C, Cogliati S, Strauch M, Grau R. 2017. Transcriptional regulation of adhesive properties of Bacillus subtilis to extracellular matrix proteins through the fibronectin-binding protein YloA: Transcriptional regulation of B. subtilis adherence to ECM components. Mol Microbiol 104:804–821.

10. Horosheva T, Vodyanoy V, Sorokulova I. 2014. Efficacy of Bacillus probiotics in prevention of antibiotic‐associated diarrhoea: a randomized, double‐blind, placebo‐controlled clinical trial. JMM Case Reports.

11. Hosoi T, Kiuchi K. Production and Probiotic Effects of NattoChapter 12. Bacterial Spore Formers: Probiotics and Emerging Applications.E. Ricca, A. O. Henriques and S. Cutting (ed.),. Horizon Bioscience.

12. Paynich ML, Jones-Burrage SE, Knight KL. 2017. Exopolysaccharide from Bacillus subtilis Induces Anti-Inflammatory M2 Macrophages That Prevent T Cell–Mediated Disease. The Journal of Immunology 198:2689–2698.

13. Zouari R, Ben Abdallah-Kolsi R, Hamden K, Feki AE, Chaabouni K, Makni-Ayadi F, Sallemi F, Ellouze-Chaabouni S, Ghribi-Aydi D. 2015. Assessment of the Antidiabetic and Antilipidemic Properties of Bacillus subtilis SPB1 Biosurfactant in Alloxan-Induced Diabetic Rats. Biopolymers 104:764–774.

14. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. 1987. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia 43:1110–1111.

15. Ayala F, Bauman C, Cogliati S, Lenini C, Bartolini M, Grau R. 2017. Microbial flora, probiotics, Bacillus subtilis and the search for a long and healthy human longevity. Nat Commun 4:133–136.

16. Donato V, Ayala FR, Cogliati S, Bauman C, Costa JG, Leñini C, Grau R. 2017. Bacillus subtilis biofilm extends Caenorhabditis elegans longevity through downregulation of the insulin-like signalling pathway. Nat Commun 8:14332.

17. Hong HA, Huang J-M, Khaneja R, Hiep LV, Urdaci MC, Cutting SM. 2008. The safety of Bacillus subtilis and Bacillus indicus as food probiotics. Appl Environ Microbiol 105:510–520.

18. Goya M, Xue F, Sampedro-Torres-Quevedo C,Ball K, Stanley-Wall N, Goya M, et al. 2020. Probiotic Bacillus subtilis protects against a-Synuclein aggregation (Parkinson disease) in C. elegans. Cell Reports 30, 367–380.

19. Cogliati S, Clementi V, Francisco M, Crespo C, Argañaraz F, and Grau R. 2020. Bacillus Subtilis Delays Neurodegeneration and Behavioral Impairment in the Alzheimer’s Disease Model Caenorhabditis Elegans. Journal of Alzheimer’s Disease, March DOI 10.3233/JAD-190837.

20. Wei G, Tian N, Siezen R, Schuppan D, and Helmerhorst E. 2016. Identification of food-grade subtilisins (nattokinase) as gluten-degrading enzymes to treat celiac disease Am J Physiol Gastrointest Liver Physiol 311: G571–G580.

21. Vollenbroich D, O¨ Zel M, Vater J, Kamp R, and Pauli G. 1997. Mechanism of inactivation of enveloped viruses (VIH) by the biosurfactant surfactin from Bacillus subtilis. Biologicals 25, 289–297.

22. Cao X, Liao Z, Wang W, Yang W, Lu F. 2009. Evaluation of a lipopeptide biosurfactant from Bacillus subtilis natto TK-1 as a potential source of anti-adhesive, antimicrobial and antitumor activities. Braz. J. Microbiol. 40:373-79.

23. Wang C, Ng T, Yuan F., Liu Z, Liu F. 2007. Induction of apoptosis in human leukemia K562 cells by cyclic lipopeptide drom Bacillus subtilis natto T-2. Peptides 28:1344-50